Welcome to the
Our lab is interested in the quantification of brain pathophysiology in patients with Alzheimer’s disease (AD) and related dementias as well as in the validation of therapies capable of modifying the course of these diseases producing an enduring disease-modifying and clinically relevant effect. This involves the validation of positron emission tomography (PET) and fluid biomarker techniques capable of measuring these brain pathologies and monitoring their progression.
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles